Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Adult
Aged
Aged, 80 and over
Antigens, Surface
/ analysis
Glutamate Carboxypeptidase II
/ analysis
Humans
Lutetium
/ administration & dosage
Male
Middle Aged
Neoplasm Metastasis
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Prospective Studies
Prostate-Specific Antigen
/ blood
Prostatic Neoplasms, Castration-Resistant
/ diagnostic imaging
Radioisotopes
/ therapeutic use
Radiopharmaceuticals
/ therapeutic use
Radiotherapy
/ methods
Single Photon Emission Computed Tomography Computed Tomography
/ methods
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
17
11
2020
revised:
22
12
2020
accepted:
02
01
2021
pubmed:
20
1
2021
medline:
19
8
2021
entrez:
19
1
2021
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) has demonstrated efficacy and tolerability with a dose-response effect in phase I/II trials in men with metastatic castration-resistant prostate cancer (mCRPC). The need for positive PSMA imaging before PSMA-TRT to select patients is largely practiced, but its utility is not proven. Given target heterogeneity, developing a biomarker to identify the optimal patient population remains an unmet need. The aim of this study was to assess PSMA uptake by imaging and response to PSMA-TRT. We performed an analysis of men with mCRPC enrolled in sequential prospective phase I/II trials of PSMA-TRT. Each patient had baseline PSMA imaging by planar 215 men with progressive mCRPC received PSMA-TRT as follows: Collectively, the data provide evidence in favor of the hypothesis that patients with high PSMA uptake and high administered radionuclide dose correlate with a higher chance of response.
Sections du résumé
BACKGROUND
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) has demonstrated efficacy and tolerability with a dose-response effect in phase I/II trials in men with metastatic castration-resistant prostate cancer (mCRPC). The need for positive PSMA imaging before PSMA-TRT to select patients is largely practiced, but its utility is not proven. Given target heterogeneity, developing a biomarker to identify the optimal patient population remains an unmet need. The aim of this study was to assess PSMA uptake by imaging and response to PSMA-TRT.
METHODS
We performed an analysis of men with mCRPC enrolled in sequential prospective phase I/II trials of PSMA-TRT. Each patient had baseline PSMA imaging by planar
RESULTS
215 men with progressive mCRPC received PSMA-TRT as follows:
CONCLUSION
Collectively, the data provide evidence in favor of the hypothesis that patients with high PSMA uptake and high administered radionuclide dose correlate with a higher chance of response.
Identifiants
pubmed: 33465252
doi: 10.1002/pros.24104
pmc: PMC7904644
mid: NIHMS1661599
doi:
Substances chimiques
Antigens, Surface
0
Radioisotopes
0
Radiopharmaceuticals
0
Lutetium
5H0DOZ21UJ
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Prostate-Specific Antigen
EC 3.4.21.77
Banques de données
ClinicalTrials.gov
['NCT00003391', 'NCT00195039', 'NCT00538668', 'NCT03545165', 'NCT03042468', 'NCT03276572']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-285Subventions
Organisme : NCI NIH HHS
ID : R01 CA207645
Pays : United States
Organisme : NIH HHS
ID : 1-KL2-RR024997-01
Pays : United States
Organisme : NIH HHS
ID : 7R01CA207645
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA142419
Pays : United States
Organisme : NCRR NIH HHS
ID : KL2 RR024997
Pays : United States
Organisme : NIH HHS
ID : ULI RR024996
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024996
Pays : United States
Organisme : NIH HHS
ID : PTBF5405
Pays : United States
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
J Nucl Med. 2019 Sep;60(9):1266-1269
pubmed: 30850506
J Nucl Med. 2020 Jun;61(6):857-865
pubmed: 31732676
J Nucl Med. 2016 May;57(5):759-64
pubmed: 26912441
J Nucl Med. 2019 Apr;60(4):517-523
pubmed: 30291192
Cancer Imaging. 2019 Jun 11;19(1):37
pubmed: 31186052
Eur Urol. 2019 Oct;76(4):469-478
pubmed: 31345636
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2322-2327
pubmed: 32140802
BJU Int. 2019 Nov;124 Suppl 1:5-13
pubmed: 31638341
Eur Urol Oncol. 2019 Nov;2(6):670-676
pubmed: 31412006
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1054-1062
pubmed: 30697649
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Clin Genitourin Cancer. 2019 Feb;17(1):15-22
pubmed: 30425003
EJNMMI Res. 2015 Apr 29;5:28
pubmed: 25984435
Semin Nucl Med. 2019 Jul;49(4):302-312
pubmed: 31227053
J Clin Oncol. 2014 Mar 1;32(7):671-7
pubmed: 24449231
Clin Cancer Res. 2013 Sep 15;19(18):5182-91
pubmed: 23714732
J Clin Oncol. 2005 Jul 20;23(21):4591-601
pubmed: 15837970
J Clin Oncol. 2004 Jul 1;22(13):2522-31
pubmed: 15173215
Oncologist. 2020 Jun;25(6):477-e895
pubmed: 31999003
J Nucl Med. 2020 May;61(5):689-695
pubmed: 31653712
Cancer. 2019 Aug 1;125(15):2561-2569
pubmed: 31012963